ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,277.51
0.80%
Dow Jones
38,686.32
1.51%
US Dollar vs MXN
16.99024
0.00%
Brent Oil
81.295
0.00%
Bitcoin
67,679.50
-0.07%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Cognition Therapeutics Inc (CGTX)

  7. Cognition Therapeutics Inc (CGTX) Noticias

CGTX

Cognition Therapeutics (CGTX)

Cognition Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:CGTX
FechaHoraFuenteTítuloSímboloCompañía
07/05/202406:45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CGTXCognition Therapeutics Inc
07/05/202406:39Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGTXCognition Therapeutics Inc
11/03/202415:06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CGTXCognition Therapeutics Inc
20/02/202415:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGTXCognition Therapeutics Inc
19/01/202414:07Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CGTXCognition Therapeutics Inc
08/01/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CGTXCognition Therapeutics Inc
08/01/202415:11Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:CGTXCognition Therapeutics Inc
04/01/202406:30GlobeNewswire Inc.Cognition Therapeutics CEO Issues Letter to ShareholdersNASDAQ:CGTXCognition Therapeutics Inc
29/12/202315:02Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CGTXCognition Therapeutics Inc
16/11/202306:30GlobeNewswire Inc.Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip ScheltensNASDAQ:CGTXCognition Therapeutics Inc
15/11/202306:30GlobeNewswire Inc.Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s DiseasesNASDAQ:CGTXCognition Therapeutics Inc
13/11/202316:25Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:CGTXCognition Therapeutics Inc
13/11/202316:17Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CGTXCognition Therapeutics Inc
07/11/202306:30GlobeNewswire Inc.Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s DiseaseNASDAQ:CGTXCognition Therapeutics Inc
02/11/202306:30GlobeNewswire Inc.Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:CGTXCognition Therapeutics Inc
27/10/202306:30GlobeNewswire Inc.Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTADNASDAQ:CGTXCognition Therapeutics Inc
24/10/202315:30GlobeNewswire Inc.Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTADNASDAQ:CGTXCognition Therapeutics Inc
16/10/202306:30GlobeNewswire Inc.Cognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS IndicationsNASDAQ:CGTXCognition Therapeutics Inc
07/09/202306:45GlobeNewswire Inc.Cognition Therapeutics Announces New Conversations Episode on Therapeutic Strategies to Protect the Retina in Dry AMDNASDAQ:CGTXCognition Therapeutics Inc
30/08/202307:00GlobeNewswire Inc.Cognition Therapeutics Announces Participation in Upcoming September ConferencesNASDAQ:CGTXCognition Therapeutics Inc
08/08/202306:00GlobeNewswire Inc.Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business UpdateNASDAQ:CGTXCognition Therapeutics Inc
02/08/202306:30GlobeNewswire Inc.Cognition Therapeutics to Report Second Quarter 2023 Results in Conference Call on Tuesday, August 8, 2023NASDAQ:CGTXCognition Therapeutics Inc
11/07/202306:30GlobeNewswire Inc.Cognition Therapeutics Announces Dosing of First Patient in MAGNIFY Study of Oral CT1812 for Geographic Atrophy Secondary to Dry AMDNASDAQ:CGTXCognition Therapeutics Inc
05/07/202306:30GlobeNewswire Inc.Cognition Therapeutics and the Alzheimer's Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 START Study in Early Alzheimer’s DiseaseNASDAQ:CGTXCognition Therapeutics Inc
28/06/202306:33Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:CGTXCognition Therapeutics Inc
28/06/202306:28Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CGTXCognition Therapeutics Inc
28/06/202306:00GlobeNewswire Inc.Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s DiseaseNASDAQ:CGTXCognition Therapeutics Inc
27/06/202318:17GlobeNewswire Inc.Cognition Therapeutics to Host Call and Webcast to Discuss Topline Results from CT1812 Phase 2 SEQUEL Study on June 28, 2023NASDAQ:CGTXCognition Therapeutics Inc
20/06/202306:30GlobeNewswire Inc.Cognition Therapeutics Invited to Participate on Panel During Cantor Fitzgerald Brain Week 2023 on Novel Alzheimer’s Disease ApproachesNASDAQ:CGTXCognition Therapeutics Inc
13/06/202316:38Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CGTXCognition Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CGTX

Su Consulta Reciente

USI
USTECH100
US Tech 100
USOTC
BNPQY
BNP Paribas (QX)
COIN
ETHUSD
Ethereum
USOTC
ADDYY
Adidas (QX)
USOTC
RHHBY
Roche (QX)
NASDAQ
TSLA
Tesla
NYSE
MRK
Merck
NYSE
MCD
McDonalds
CCOM
SILVER
SILVER
NYSE
VZ
Verizon Communications
CCOM
OILBRENT
Brent Oil
NYSE
JPM
JP Morgan Chase
NYSE
NKE
Nike
NASDAQ
GOOGL
Alphabet
NASDAQ
AMZN
Amazon.com
NYSE
XOM
Exxon Mobil
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados